Research Library

Science, technology, and innovation are vital to America’s economy and workforce, and the competitiveness of U.S. industry. The authors offer five recommendations to ensure the establishment of an effective White House Office of Science and Technology Policy.

The United States has a unique opportunity to reduce the spread of disease by engaging the leaders of the G20 countries and targeting neglected diseases. Fellow Peter Hotez explains how.

With growing competition from abroad, the U.S. must reform its fiscal policy to reduce debt, maximize economic efficiency — including minimizing the distortions caused by the tax system — and maintain its areas of competitive advantage.

There is broad consensus in the medical and scientific community that substance abuse should be treated as a medical and public health problem, not a crime. The authors recommend a sensible pivot from failed policies of drug prohibition toward a realistic approach to drug use.

This issue brief argues that continued investments in global health and the study of emerging pathogens could yield better tools to fight infectious diseases like the Zika virus long before they become a problem in the developed world.

This policy brief urges collaboration between the United States and Mexico to address widespread epidemics of mosquito-transmitted diseases like West Nile, dengue and chikungunya in both countries. Such policy development should focus on vector control programs, public awareness and the development of vaccines to curb the spread of these diseases.

Officials in the U.S. and Mexico should coordinate a response to the spread of Chagas disease in their countries. Chagas is the third most common parasitic infection in the world.

The human papillomavirus (HPV) affects over 80 million Americans, causing more than 40,000 cases of HPV-associated cancers in the U.S. In 2006, the FDA licensed the first HPV vaccine, which could help save thousands of lives; no cure for HPV currently exists. However, the political controversy raised by the vaccine has limited its acceptance and use. Such resistance potentially jeopardizes an opportunity to reduce cancer rates in Texas and the broader United States.